Tencent and Gilead Sciences took part in a round that will fund clinical trials for three of Vaccitech's vaccine product candidates.
Vaccitech, a UK-based developer of vaccines for infectious diseases, closed a $168m series B round today backed by internet group Tencent and biopharmaceutical company Gilead Sciences.
The round was led by M&G Investment Management, a division of impact investment manager M&G, and included Oxford Sciences Innovation, Future Planet Capital, the state-owned Monaco Constitutional Reserve Fund and unnamed new and existing investors.
Founded in 2016, Vaccitech was launched with the aim of developing a universal flu vaccine and has built a…
